

Wake Forest University School of Medicine

Curriculum Vitae

NAME: P. Samuel Pegram, M.D., F.A.C.P.

ADDRESS:

BUSINESS: Department of Internal Medicine
Section on Infectious Diseases
Wake Forest University Health Sciences
Medical Center Boulevard
Winston-Salem, North Carolina 27157-1042

Telephone: (336) 716-4262
Fax: (336) 716-3825

EDUCATION:

1962-1966 University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
A.B. - Chemistry (Honors)

Merit Scholarship (Sears) – 1962
Phi Eta Sigma (National Freshman Scholastic Honor Society) 1963
Alpha Epsilon Delta (International Premedical Honor Society)
Vice President – 1966
Phi Beta Kappa – 1966

EDUCATION (continued):

1966-1970 Bowman Gray School of Medicine of Wake Forest University
Winston-Salem, North Carolina
M.D.

Z. Smith Reynolds Scholarship for Medical Education
1966-1970
Student Research Fellowship – 1967 and
1968
Alpha Omega Alpha – 1970
Annual OB/Gyn Student Award – 1970
Upjohn Achievement Award - "Senior student possessing the qualities of the complete physician" - 1970

FOREIGN FELLOWSHIP:

1969 Frank Lock Foreign Fellowship for Medical Education
University College Hospital
Department of Obstetrics and Gynecology
University of London
London, England

POSTDOCTORAL TRAINING:

1970-1971 Rotating Internship
North Carolina Baptist Hospital
Winston-Salem, North Carolina

1973-1975 Residency - Internal Medicine
North Carolina Baptist Hospital
Winston-Salem, North Carolina

1975 Chief Residency - Internal Medicine
North Carolina Baptist Hospital
Winston-Salem, North Carolina

1976-1978 Fellowship - Infectious Diseases
North Carolina Baptist Hospital
Winston-Salem, North Carolina

1989 Fellow - Infectious Diseases Society of America
AIDS Training Program
San Francisco General Hospital
San Francisco, California

UNIFORMED SERVICE:

1971-1973 United States Navy
Lieutenant - Medical Corps
USNS Subic Bay, Philippines
Flight Surgeon - U.S. Constellation CVA-64

1974-1979 LCdr - USNR - Inactive Reserves

COMMENDATIONS:

Viet Nam Campaign Medal
Philippines Presidential Medal

PROFESSIONAL LICENSURE:

June 1980 North Carolina - #16925

SPECIALTY CERTIFICATION:

1976 Diplomate
American Board of Internal Medicine

1978
Diplomate
Subspecialty in Infectious Diseases

EMPLOYMENT:

2000-Present
Professor of Medicine with tenure
Section on Infectious Diseases and Immunology
Wake Forest University School of Medicine
Winston-Salem, North Carolina

1992- 2000
Professor of Medicine
Section on Infectious Diseases and Immunology
Wake Forest University School of Medicine
Winston-Salem, North Carolina

1983-1992
Associate Professor of Medicine
Section on Infectious Diseases and Immunology
Bowman Gray School of Medicine
Winston-Salem, North Carolina

1978-1983
Assistant Professor of Medicine
Section on Infectious Diseases and Immunology
Bowman Gray School of Medicine
Winston-Salem, North Carolina

EMPLOYMENT (continued):

1983-Present
Director
Infectious Diseases Specialty Clinic
Wake Forest University Physicians

OTHER PROFESSIONAL APPOINTMENTS AND ACTIVITIES:

1974-1975
President
House staff Association
North Carolina Baptist Hospital

1974-1975
Graduate Medical Education Committee
North Carolina Baptist Hospital

1975-1986
Infection Control Committee
North Carolina Baptist Hospital
Chairman - 1979-1984

1978-1984
Infection Control Committee
Forsyth Memorial Hospital

1978-1984
Hospital Epidemiologist
Forsyth Memorial Hospital
Winston-Salem, North Carolina

1978
Utilization and Review Committee

North Carolina Baptist Hospital

1980-1984 Quality Assurance Committee
North Carolina Baptist Hospital

1980-1981 Medical School Admissions Committee
Bowman Gray School of Medicine

1980-1990 Medical School Promotions Committee
Bowman Gray School of Medicine

1980-1990 Committee on Evaluation of Clinical Competence
American Board of Internal Medicine
Bowman Gray School of Medicine

1981-1982 House Staff Education Committee
North Carolina Baptist Hospital

1981-1992 Councilor
Alpha Omega Alpha
Bowman Gray School of Medicine

OTHER PROFESSIONAL APPOINTMENTS AND ACTIVITIES: (continued)

1981-1990 Intensive Care Unit Committee
North Carolina Baptist Hospital

1983-2002 Pharmacy and Therapeutics Committee
North Carolina Baptist Hospital
Chairman – 1997 to 2002

1983-1990 Department of Clinics Committee
North Carolina Baptist Hospital

1984-1990 Medical Committee of Planned Parenthood of the
Triad, Inc., Winston-Salem, North Carolina

1984-2000 Clinical Mentor for Medicine as a Career program

1984-1994 Committee on International Health Affairs
Bowman Gray School of Medicine

1985-1993 Chairman, Human Immunodeficiency Virus (HIV)
Infection Committee
Bowman Gray School of Medicine

1986-1992 AIDS Task Force
Wake Forest University

1992-2000	Health Advisory Board Wake Forest University School of Medicine
1986-1988	Task Force for Ambulatory Care Facilities for Day Hospitals and Observation Beds
1987-1990	Board of Directors AIDS Task Force of Winston-Salem
1986-1996	Task Force for Sexually Transmitted Diseases and AIDS of the North Carolina Medical Society Chairman – 1993-1994

PROFESSIONAL INTERESTS:

Research interests center on clinical efficacy and safety studies of antimicrobials, sexually transmitted diseases, human immunodeficiency virus infection, and infections in oncology patients.

GRANTS:

Protocol BG03-522, "A rollover study for subjects on capravirine who wish to continue treatment with open-label capravirine after completing study A4311002". Agouron. Pegram PS, Principal Investigator. \$4515/pt.

Protocol: BG03-383, "A phase III, randomized, open-label, multicenter study of the treatment of antiretroviral-naïve, HIV-1-infected subjects comparing tenofovir disoproxil fumarate and emtricitabine in combination with efavirenz versus Combivir (lamivudine/zidovudine) and efavirenz". Gilead. Pegram PS, Principal Investigator. \$5,631/pt.

Protocol: BG 03-163, "A phase 2, randomized, double-blind, dose-ranging study of capravirine (AG 1549) in combination with Kaletra and at least 2 nucleoside reverse transcriptase inhibitors in HIV-infected subjects who have failed antiretroviral regimens containing protease inhibitors, nonnucleoside reverse transcriptase inhibitors". Agouron. Pegram PS, Principal Investigator. \$7,180/pt.

Protocol A4311006 (BG 03-400), "A rollover study for subjects continuing treatment with open-label capravirine who were enrolled in study A4311006." Agouron. Pegram PS, Principal Investigator. \$6,165/pt.

Protocol BG03-158, "A large, simple trial comparing two strategies for a management of anti-retroviral therapy (The Smart Study) (CPCRA 065)". NIH, CPCRA. Pegram PS, Co-Investigator. \$95,809.

Protocol M02-418 (BG02-291), "A randomized open-label study of 800 mg Lopinavir/1200 mg Ritonavir QD in combination with tenofovir and emtricitabine vs. 400 mg Lopinavir/100 mg Ritonavir BID in combination with Tenofovir and Emtricitabine in HIV-infected antiretroviral naïve subjects. Abbott. Pegram PS, Co-Investigator. \$5,531/pt.

Protocol: BG02-319, "A double-blind, randomized, placebo-controlled study of capravirine

(AG1549) in combination with Viracept and two nucleoside reverse transcriptase inhibitors in HIV-infected patients who failed an initial nonnucleoside reverse transcriptase containing regimen". Agouron. Pegram PS, Principal Investigator. \$5,360/pt.

Protocol: BG02-350, "Zest-QD: A phase IIB, open-label, randomized, multicenter study switching HIV-1 infected subject with a viral load of <50 copies/mL on a BID or more frequent initial HAART regimen to a once daily regimen including Stavudine XR, Lamivudine, and Efavirenz. Bristol-Myers Squibb. Pegram PS, Principal Investigator. \$12,500.

Protocol M02-418. "A randomized open-label study of 800 mg Lopinavir/200 mg Ritonavir QD in combination with Tenofovir and Emtricitabine vs. 400 mg Lopinavir/100 mg Ritonavir BID in combination with Tenofovir and Emtricitabine in HIV-infected antiretroviral naïve subjects."

GRANTS: (continued)

Grant 8703D. IND protocol 9 "Clinical evaluation of LY 127935 in infections" Eli Lilly and Company Co-investigator: McCall CE 1980: \$30,420

Protocol 2190B "RO 13-9904 in the parenteral therapy of serious bacterial infections" Hoffmann-La Roche Incorporated Co-investigator: McCall CE 1980: \$23,400

Grant 9348D "A randomized trial of empiric therapy of moxalactam disodium versus tobramycin ticarcillin in infected neutropenic cancer patients" Eli Lilly and Company Co-investigators: McCall CE, Muss H, et al 1981: \$56,250

Protocol B-804-A "Study of the efficacy and safety of cefonicid in infection prophylaxis in cholecystectomy" Smith Kline and French Laboratories Co-investigators: McCall CE, Sterchi M, et al 1981: \$90,200

Protocol 2407 "Ceftriaxone once daily in the parenteral therapy of bacterial infections" Hoffmann-La Roche Incorporated 1981: \$30,680

Protocol BG82-0065 "Cefoperazone Na in the treatment of various infections of bacterial etiology" Pfizer Pharmaceuticals 1982

Protocol 20311-01 "Open-label safety and efficacy study of parenteral BRL 28500 (ticarcillin/clavulanic acid) in the treatment of hospitalized patients with systemic or urinary tract infections" Beecham Laboratories 1982: \$40,000

Protocol BG83-0260 "A multicenter blind evaluator study comparing the efficacy and tolerance of netilmicin-piperacillin with the efficacy and tolerance of tobramycin piperacillin in cancer patients with presumed serious systemic infections" Schering Corporation 1983: \$65,346

Protocol BG83-0331 "Comparison of chronic suppressive to acute oral acyclovir therapy in the management of recurrent genital herpes" Burroughs Wellcome Company Co-investigator: Peacock JE Jr. 1983: \$32,500

Protocol BG 84 "A comparison of cefoperazone plus tobramycin versus mezlocillin plus tobramycin in the therapy of leukopenic patients with fever" Pfizer Pharmaceuticals 1984: \$241,020

Protocol CA2-A01 "An open clinical evaluation of ceftazidime in the treatment of acute infection" Glaxo, Incorporated 1984: \$41,636

Protocol BG 86-0120 "Tazidime-Nebcin versus Tazidime-Amikacin in life threatening infection" Lilly Research Laboratories 1986: \$45,240

Protocol F85-108 "Randomized study to evaluate the safety and efficacy of ofloxacin versus cephalexin in the treatment of skin, skin structure and soft tissue infections in adults" Ortho Pharmaceutical Corporation 1986: \$45,000

GRANTS: (continued)

Protocol BG-0281 "A comparison of cefoperazone plus ampicillin/sulbactam vs. ceftazidime plus vancomycin in the therapy of neutropenic patients with fever" Pfizer Pharmaceuticals (Roerig Division) 1986: \$96,000

Protocol BG 86-0280 "A randomized blinded comparative study of teicoplanin vs. vancomycin in the treatment of vascular-access associated bacteremia/septicemia caused by gram positive bacteremia" Merrell Dow Pharmaceuticals 1987: \$54,012

Protocol BG-86-0282 "IM cefmetazole, cefoxitin or penicillin for the treatment of uncomplicated gonococcal infections" Upjohn Pharmaceuticals 1987: \$92,250

Protocol BG86-0259 "An open non-comparative multicenter study of the efficacy, safety, and toleration of fluconazole given orally in the treatment of fungal disease in patients with the acquired immunodeficiency syndrome" Pfizer-Groton 1987: \$39,109

Protocol 056-150 "A randomized comparative multicenter trial of fluconazole and ketoconazole in the treatment of esophageal candidiasis in immunocompromised patients" Pfizer-Groton 1987: \$40,000

Protocol BG88-0213 "A multicenter comparison of the safety and efficacy of lomefloxacin and cefaclor in the treatment of acute exacerbation of chronic bronchitis" Schering 1988: \$18,000

Protocol BG88-0214 "Multicenter comparison of fluconazole (UK 49,858) and amphotericin B as maintenance treatment for the prevention of relapse of cryptococcal meningitis in patients with acquired immunodeficiency syndrome" Pfizer-Groton 1988: \$30,000

Protocol BG88-0252 "The efficacy and safety of Retrovir in patients infected with HIV who are asymptomatic (CDC Group II) or have persistent generalized lymphadenopathy (CDC Group III)" Burroughs-Wellcome Company 1988: \$14,000

Protocol BG88-025 "A multicenter, double-blind trial to evaluate the safety and efficacy of concurrent Retrovir (zidovudine) and Zovirax (acyclovir) therapy in patients with early symptomatic human immunodeficiency virus (HIV) infection" Burroughs-Wellcome Company 1988: \$184,615

Protocol BG89-0212 "A randomized double-blind, comparative study of dideoxycytidine (ddC) versus zidovudine (ZDV) in patients with AIDS or advanced ARC" Hoffman-La Roche Laboratories 1989: \$144,600

North Carolina Medical Society Foundation "HIV Mini fellowship Program" 1991: \$5,000

Protocol BG92-0039 "A multicenter, double-blind, randomized comparative study of the efficacy and safety of intravenous temafloxacin vs. imipenem-cilastatin sodium in the treatment of intra-abdominal infection"

Protocol BG92-0333 "Comparison of oral cefpodoxime proxetil with parenteral ceftriaxone in treatment of acute community-acquired pneumonia" Upjohn Pharmaceuticals 1992: \$30,000

GRANTS: (continued)

Protocol BG92-0334 "Radionuclide imaging of HIV-infected patients with central nervous system pathology" 1992

Protocol BG93-0036 "Randomized, controlled, double-blind study of itraconazole oral solution vs. Fluconazole tablets in the treatment of esophageal candidiasis" Jansen Research Foundation 1992

Protocol BG94-226 "A randomized, controlled, multicenter trial of filgrastim (recombinant-methionyl human granulocytic colony stimulating factor) for the prevention of grade 4 neutropenia in patients with HIV infection" Amgen, Inc. 1994

Protocol BG95-44 "A non-comparative, multi-site, open-label, 48 week study to monitor the safety and tolerability of MK-0639 (Indinavir sulfate 800mg z8h) administered as monotherapy or in combination with reverse transcriptase Inhibitor therapy for the treatment of HIV-1 infection in advanced AIDS patients (patients with CD4 counts of 50 cell/mm³ or less) 1995

Protocol BG96-002 "A multicenter, rising, multiple-dose, placebo-controlled, dose-response tolerability, and antiviral activity of four weeks of treatment with 200-800 mgm fozivudine ti Doxid in patients with HIV-1 infection" Boehringer Mannheim 1996

Protocol BG97-329 "Randomized double-blinded placebo-controlled trial of treatment of HIV-associated nephropathy with glucocorticoids, captopril or placebo" Co-Investigator: Appel R, High K, Peacock JE. 1997

Protocol BG99-613 "A multicenter, open-label, 24-week study to evaluate the efficacy and safety of indinavir sulfate 800 g and ritonavir 200 mg bid plus 2 NRTIs bid in HIV-1 infected individuals who require early treatment intervention.

Protocol BG98-051 "Open-label study to compare antiretroviral activity and tolerability of three different combination regimens (DMP266+indinavir, DMP266+ zidovudine+lamivudine, indinavir+zidovudine+lamivudine) in HIV-infected patients"

Protocol BG99-343 "A randomized, double-blind, dose ranging study to access the safety and tolerability of three doses of DPC 961 versus efavirenz in combination with open label zidovudine and lamivudine in antiretroviral naive HIV-1 infected patients"

Protocol BG99-342 "Evaluation of the safety and antiretroviral activity of stavudine extended release formulation as compared to stavudine immediate release formulation, each as part of potent antiretroviral combination therapy"

Protocol BG00-070 "ABT-378/r (ABT-378Ritonavir) early access program"

Protocol BG00-262 "A phase III, randomized, double-blind, multicenter study of the treatment of antiretroviral-naïve, HIV-1 infected patients comparing tenofovir disoproxil fumarate administered in combination with lamivudine and efavirenz versus stavudine, lamivudine and efavirenz"

GRANTS: (continued)

Protocol BG00-258 "A double-blind, randomized, placebo-controlled study of AG1549 in combination with VIRACEPT and two nucleoside reverse transcriptase inhibitors in HIV-infected subjects who failed an initial non-nucleoside reverse transcriptase inhibitor containing regimen"

Protocol BG01-044 "A study to compare long-term safety and tolerability of Stavudine (D4T) extended release (ER) versus conventional, (Immediate Relapse, IR) formulations, each in combination with lamivudine (3TC) and Efavirenz (EFV) in subjects who have completed BMS studies A1455-096 and A1455-099"

Protocol BG01-525 "A randomized, open-label study of the antiviral efficacy and safety of Atazanavir, in combination with Ritonavir or Saquinavir, and the combination of Lopinavir/Ritonavir each with Tenofovir and a Nucleoside in subjects who have experienced virologic failure"

Protocol BG01-492 "A randomized, open-label study of the antiviral efficacy and safety of Atazanavir versus Lopinavir/Ritonavir (LPV/RTV), each in combination with two nucleosides in subjects who have experienced virologic failure with prior protease inhibitor-containing HAART regimen(s)"

Protocol BG01-524 "A phase III study comparing the antiviral efficacy and safety of Atazanavir with Nelfinavir; each in combination with dual nucleoside therapy in HIV-infected subjects who have failed a regimen not containing a protease inhibitor"

Protocol BG02-055 "Double-blind, randomized, dose optimization trial of three doses of tipranavir boosted with low dose ritonavir (TPV/RTV) in multiple antiretroviral drug-experienced subjects.

Protocol BG02-056

Long-Term Open-Label Rollover Trial Assessing the Safety and Tolerability of Combination tipranavir and ritonavir Use in HIV-1 Infected Subjects

Protocol BG02-256

A Long Term open label rollover trial assessing the safety and tolerability of combination tipranavir and Ritonavir use in HIV-1 infected subjects.

Protocol BG02-319

A Double-blind, Randomized, Placebo-controlled Study of Two Doses of Capravirine (Ag1549) in Combination with Viracept and Two Nucleoside Reverse Transcriptase Inhibitors in HIV-infected Patients Who Failed an Initial Nonnucleoside Reverse Transcriptase Inhibitor Containing Regimen.

Protocol: BG02-291

A Randomized Open-Label Study of 800mg Lopinavir/200mg Ritonavir QD in Combination with Tenofovir and Emtricitabine vs. 400mg Lopinavir/100mg Ritonavir BID in Combination with Tenofovir

and Emtricitabine in HIV -Infected Antiretroviral Naïve Subjects. Protocol Number-M02-418

GRANTS: (continued)

Protocol: BG02-350

Zest-QD: A Phase IIIB, Open-Label, Randomized, Multicenter Study Switching HIV-1 Infected Subjects with a Viral Load of <50 Copies/mL on a BID or More Frequent Initial HAART Regimen to a Once Daily Regimen Including Stavudine XR, Lamivudine and Efavirenz

Protocol BG03-522

A Rollover Study for Subjects on Capravirine Who Wish to Continue Treatment with Open-Label Capravirine after Completing Study A4311002

Protocol: BG03-383

A Phase III, Randomized, Open-Label, Multicenter Study of the Treatment of Antiretroviral-Naïve, HIV-1-Infected Subjects Comparing Tenofovir Disoproxil Fumarate and Emtricitabine in Combination with Efavirenz Versus Combivir (lamivudine/zidovudine)) and Efavirenz

Protocol: BG03-158

A Large, Simple Trial Comparing Two Strategies for a Management of Anti-Retroviral Therapy (The Smart Study)

Protocol BG03-055

Randomized, open-label, comparative safety and efficacy study of tipranavir boosted with low dose ritonavir (TPV/RTV) versus genotypically-defined protease inhibitor/ritonavir (PI/RTV) in multiple antiretroviral drug-experienced patients (Resist 1: Randomized Evaluation of Strategic Intervention in Multi-Drug Resistant Patients with Tipranavir)

Protocol BG-04-496

A Phase IV, Multi-center, Cross-Sectional Study to Evaluate the 150L Substitution among Subjects Experiencing Virologic Failure on a HAART Regimen Containing Atazanavir (ATV)

Protocol BG04-496

A Phase IV, Multi-center, Cross-Sectional Study to Evaluate the 150L Substitution among Subjects Experiencing Virologic Failure on a HAART Regimen Containing Atazanavir (ATV)

Protocol BG04-157

A Phase IIIB, Open-Label, Randomized, Multi-center Study Comparing the Antiviral Efficacy, safety, and Effect on Serum Lipids of Atazanavir/Ritonavir Versus Lopinavir/Ritonavir, each in Combination with Tenofovir and either Didanosine EC or Stavudine XR in HIV-1 Infected Subjects Receiving a NNRTI-Containing HAART Regimen who are Experiencing their First Virologic Failure

Protocol BG04-646

Combination of **E**favirenz and **T**ruvada (The COMET study): A Phase 4 Evaluation of Switching from Twice Daily Zidovudine and Lamivudine (Combivir) to a Simplified, Once-Daily Regimen of Co-formulated Emtricitabine and Tenofovir Disoproxil Fumarate (Truvada), in Virologically Suppressed, HIV-Infected Patients Taking Efavirenz

GRANTS: (continued)

Protocol BG05-255

A Randomized, Controlled, Open-Label Trial to compare the efficacy, safety, and tolerability of TMC114/RTV versus LPV/RTV in Treatment-Experienced HIV-1 infected subjects.

Protocol BG05-598

TMC125-C206; A Phase III Randomized, Double-blinded, Placebo-Controlled Trial to Investigate the Efficacy, Tolerability and Safety of TMC-125 as Part of an ART Including TMC114/RTV and an Investigator-selected OBR in HIV-1 Infected Subjects with Limited to no Treatment Options.

Protocol BG05-599

A Randomized, Controller, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/Ritonavir Versus Lopinavir/Ritonavir in Treatment-naïve HIV-1 Infected Subjects: ARTEMIS.

Protocol BG05-371

A Phase IIb, Randomized, Partially Blinded, Dose-Finding Trial of TMC278 in Antiretroviral Naïve HIV-1 Infected Subjects.

Protocol BG05-476

A Randomized, Open-Label, Two-Way Crossover Study to Assess the Tolerability of the B2000 Needle-Free Injection Device (NFID) for Administration of Enfuvirtide (ENF)

HIV-AIDS Bureau (Pegram) 9/30/03- 4/1/07
HRSA \$300,000/year
A Ryan White Title III HIV Primary Care Early Intervention Services Grant
Role: Co-Principal Investigator 15% Effort

HIV/STD Prevention and Care Branch (Pegram) 7/04-7/05
NCDHHS \$93,333
Ryan White Title II grant to provide HIV primary care services
Role: Co-Principal Investigator 0% Effort

HIV-AIDS Bureau (Pegram) 8/04-7/07
HRSA \$50,000/year
A Ryan White Title III HIV Primary Care Capacity Building Grant
Role: Co-Principal Investigator 5% Effort

HIV/STD Prevention and Care Branch (Pegram) 7/05-7/06
NCDHHS \$93,333
Ryan White Title II grant to provide HIV primary care services
Role: Co-Principal Investigator 0% Effort

NIH/DAIDS/CPCRA

A large, simple trial comparing two strategies for management of antiretroviral therapy (THE SMART STUDY). Community Programs for Clinical Research on AIDS Associate Site.

Role: Co-Principal Investigator 0% Effort

PROFESSIONAL MEMBERSHIPS:

American College of Physicians Fellow
American Federation for Clinical Research
American Medical Association
American Venereal Disease Association
Association for Practitioners in Infection Control
Forsyth County Medical Society
Infectious Disease Society of America
North Carolina Medical Society
American Society for Microbiology
South Atlantic Association of Obstetricians and
Gynecologists Honorary Fellow (1989)
International AIDS Society
International Association of Physicians in AIDS Care
European AIDS Clinical Society

HONORS AND AWARDS:

1975	Annual House Officer Award (Excellence in Clinical Teaching) Bowman Gray School of Medicine
1978	Annual House Officer Award (Excellence in Clinical Teaching) Bowman Gray School of Medicine
1978-Present	Medical Foundation Clinical Teaching Scholar Bowman Gray School of Medicine
1979	Medicine House staff Award for Teaching Excellence North Carolina Baptist Hospital
1980	Award in Teaching Excellence - Faculty (Clinical Teaching) Bowman Gray School of Medicine
1988	Teaching Excellence Award Bowman Gray School of Medicine
1988	Yearbook Dedication - Class of 1988 Bowman Gray School of Medicine
1996	Annual Clinical Faculty Award Bowman Gray School of Medicine
2000	Faculty Teaching Excellence Award Bedside Teaching Wake Forest University School of Medicine

- 2000 Distinguished Alumni Service Award
Wake Forest University School of Medicine
- 2001 Master Teacher Award
Department of Internal Medicine
Wake Forest University School of Medicine

BIBLIOGRAPHY:

Monographs and Books:

Pegram PS Jr., Johnson JE III. Antibiotics in clinical medicine: Case studies. Garden City, NJ: Medical Examination, 1981.

Contributing editor. The critical care drug handbook. St. Louis, MO. Mosby Year Book. 1991.

Chapters in Books:

Philip JR, Pegram PS Jr., Deal WB. Selected references. In: Cluff LE, Johnson JE III, Eds. Clinical concepts of infectious diseases, 2nd Ed. Baltimore: Williams & Wilkins, 1978:492-513. (Clinical Concepts in Medicine Monograph Series).

Pegram PS Jr., Johnson JE III. Abscesses. In: Cluff LE, Johnson JE III, eds. Clinical concepts of infectious disease, 3rd Ed. Baltimore: Williams & Wilkins, 1982:129-139.

Holmes KK, Corey L, Pegram PS Jr. Sexually transmitted diseases. In: Cluff LE, Johnson JE III, Eds. Clinical concepts of infectious disease, 3rd Ed. Baltimore: Williams & Wilkins, 1982:232-251.

Pegram PS Jr., Philip JR. Selected references. In: Cluff LE, Johnson JE, eds., Clinical concepts of infectious diseases, 3rd Ed. Baltimore: Williams & Wilkins, 1982:337-346.

Pegram PS Jr. Prevention of communicable disease in Medical Personnel. In: American College of Emergency Physicians. Critical decisions in emergency medicine, Vol. 1: American College of Emergency Physicians, 1984:1-7.

Pegram PS Jr., Meningitis. In: Internal medicine case studies: a complication of 58 clinical studies. New Hyde Park, NY: Medical Examination, 1985:202-210.

Pegram PS. Rocky Mountain Spotted fever. In: Internal medicine case studies: a complication of 58 clinical studies. New Hyde Park, NY: Medical Examination, 1985:183-191.

Craig J, Pegram PS. Overwhelming post splenectomy infection. In: Internal medicine case studies: a complication of 58 clinical studies. New Hyde Park, NY: Medical Examination, 1985:192-201.

Bernstein J, Gorse G, Linzmayer I, Pegram S, Levin R. Randomized comparison of netilmicin and piperacillin with tobramycin and piperacillin in the empiric therapy of infections in compromised hosts. In: Ishigami J, Ed. Recent advances in chemotherapy: antimicrobial section 3: proceedings of the 14th International Congress of Chemotherapy, Kyoto 1985. Tokyo: University of Tokyo Press, 1985:2105-2106.

Pegram S. The relationship of AIDS to cancer. In: Atwell BM, Michiellutte R, eds. Understanding cancer: an introductory handbook. Winston-Salem, North Carolina: Bowman Gray School of Medicine, 1986:166-170.

Pegram PS. Esophagitis in the immunocompromised patient. The Esophagus edited by DO Castell, Little Brown and Company. Boston, Mass. 1991.

Chen MYM, Pegram PS, Zagoria RJ. Immunologically related diseases. Chen MYM, Zagoria RJ, Ott DJ, Gelfoand DW, Eds. In: Radiology of the small bowel. Igoku-Shoin. 1992. New York.

Pegram PS. Esophagitis in the immunocompromised patient. The Esophagus edited by DO Castell, Little Brown and Company. Second Edition. Boston, Mass. 1995.

Contributor In: The Critical Care Drug Handbook, 2nd Edition. Ed. Zaloga GP and MacGregor D. Mosby-Year Book, Inc. 1997.

Pegram PS. Itch in HIV infection. In: Yosipovitch G, ed. Itch Basic Mechanism and Therapy. Williams and Wilkins, 2004:152-163.

Pegram PS, Stone S. Diphtheria. In: UpToDate. 2005

JOURNAL ARTICLES:

Burt RL, Pegram PS Jr, Leake NH. Effect of placental lactogenic hormone on glycine-1-C14 incorporation into liver protein of the rat. Am J Obstet Gynecol 103:44-47, 1969.

Pegram PS Jr., Philp JR. Managing anaerobic infections. Am Fam Physician 17:186-195, 1978.

Pegram PS Jr., DeChatelet LR, McCall CE. Comparison of myeloperoxidase activity in leukocytes from normal subjects and patients with chronic granulomatous disease. J Infect Dis 138:699-702, 1978.

Marx R, Pegram PS, Wasilauskas B. Pencillin-resistant viridans streptococcal endocarditis. Morb Mort Weekly Rep 28:327-333, 1979.

Pegram PS Jr. *Staphylococcus aureus* antibiotic resistance. Am Fam Physician 24:165-170, 1981.

Pegram PS Jr., Mountz J, O'Bar P. Ethambutol-induced toxic epidermal necrolysis. Arch Intern Med 141:1677-1678, 1981.

Salzer W, Pegram PS Jr., McCall CE. Clinical evaluation of moxalactam: Evidence of decreased efficacy in gram-positive aerobic infections. Antimicrob Agents Chemother 23:565-570, 1983.

- Pegram PS Jr., Sessler CN, London WL. Lyme disease in North Carolina. *South Med J* 76:740-742, 1983.
- Pegram PS Jr., Kerns FT, Wasilauskas BL, Hampton KD, Scharyj M, Burke JG. Successful ketoconazole treatment of protothecosis with ketoconazole-associated hepatotoxicity. *Arch Intern Med* 143:1802-1805, 1983.
- Sandberg ET, Pegram PS, Roddy RE, Handsfield HH, Hampton KD, Shafran KM, Hook EW III. Dose ranging study of cefpimizole (U-63196E) for treatment of uncomplicated gonorrhea in men. *Antimicrob Agents Chemother* 29:849-857, 1986.
- Pegram S. Sexually transmitted diseases. *Crit Decisions Emerg Med* 2 (lesson 8):2-8, 1986.
- Bernstein JM, Gorse GJ, Linzmeyer MI, Pegram PS, Levin RD, Brummett RE, Markowitz N, Saravolatz LD, Lorber RR. Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients. *Arch Intern Med* 146:2329-2334, 1986.
- Gower DJ, Barrows AA III, Kelly DI Jr., Pegram S Jr. Gram-negative bacillary meningitis in the adult: review of 39 cases. *South Med J* 79:1499-1502, 1986.
- Weiss RA, Cheingsong-Popov R, Clayden S, Pegram S, Tedder RS, Barzilai A, Rubenstein E. Lack of HTLV-1 antibodies in Africans. *Nature* 319:794-795, 1986.
- Semble EL, Agudelo CA, Pegram PS. Human parvovirus B19 arthropathy in two adults after contact with childhood erythema infectiosum. *Am J Med* 83:560-562, 1987.
- Pegram PS Jr. Respiratory-tract infections in the elderly. *Geriatr Med Today* 7:27-28,31-32,35,37,40, 1988.
- Pegram PS. Human immunodeficiency virus infection. *NC Med J* 50:151-154, 1989.
- Pegram PS, Tashjian L. Meningococcemia in patients with granulocytopenia. *Cancer Bull* 41:120-121, 1989.
- Pegram PS, Phair JP, McMahan R, Murphy RL, Gordon LI, Washton H, Faubion C, Saviteer S, Cohen MS. Prospective comparative trial of short course (four days) and continuous tobramycin in combination with cefoperazone or mezlocillin in febrile, granulocytopenic patients. *J Antimicrob Chemother* 24:591-604, 1989.
- Peacock JE, Pegram PS, Leone PA, Weber SF. Prospective, randomized comparison of intravenous/ oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections. *Am J Med* 87(suppl 5A):185S-190S, 1989.
- Pegram PS, Indorf A. Esophageal Ulceration related to zalcitabine (ddC). *Ann Int Med* 117:133-134, 1992.
- Wofford JL, Matthews KR, Beech JW, Harkness GE, Pegram PS. Detection of sexually transmitted disease at premarital examination in a community health clinic. *NC Med J* 53:1-6, 1992.
- Chiu A, Pegram PS, Haponik EF. Hypersensitivity pneumonitis: A diagnostic dilemma. *J Thorac Imaging* 8:69-78, 1993.
- Kaplowitz LG, Baker D, Gelb L, Blythe J, Hale R, Frost P, Crumpacker C, Rabinovich S, Peacock Jr. JE, Herndon J, David G, Acyclovir Study Group. Prolonged continuous acyclovir

treatment of normal adults with frequently recurring genital herpes simplex virus infection. *JAMA* 265:747-751, 1991.

Indorf AS, Pegram PS. Esophageal ulceration related to zalcitabine (DDC). *Ann Intern Med* 117:133-134, 1992.

Ely EW, Pegram PS, Haponik EF. Working up the elderly patient with pneumonia. *J Resp Dis* 15:222-234, 1994.

Ely EW, Pegram PS, Haponik EF. Managing and preventing pneumonia in the elderly. *J Resp Dis* 15:295-311, 1994.

Chin RC, Jones DF, Pegram PS, Haponik EF. Complete endobronchial occlusion by Kaposi's sarcoma in the absence of cutaneous involvement. *Chest* 105:1581-1582, 1994.

Indorf AS, Pegram PS. Use of doxycycline in the management of a patient with toxoplasmic encephalitis. *AIDS* 8:1633-1634, 1994.

Percival A, Drusano GL, Beam TR, Louie T, Pegram PS, Rolston KVI. Uses of quinolones for prophylaxis - Panel Discussion. *Infectious Disease in Clinical Practice* 3:S210, 1994.

Bozette SA, Kanouse DE, Berry S, Duan N and Roche N3300/ACTG 114 Study Group. Health status and function with zidovudine or zalcitabine as initial therapy for advanced HIV disease: A randomized placebo-controlled trial. *JAMA* 273:295-301, 1995.

Horn CA, Washburn RG, Peacock JE, Pegram PS. Azole-resistant progressive oropharyngeal and esophageal candidiasis in patients with AIDS: a re-emerging indication for amphotericin B. *AIDS* 9:533-534, 1995.

Barber BA, Crotty, JM, Washburn RG, Pegram PS. *Cryptococcus neoformans* myositis in a patient with AIDS. *Clin Inf Dis* 21:1510-1511, 1995.

Greven CM, Ford J, Stanton C, Shogreen M, Feldman S, Pegram S, Slusher MM. Progressive outer retinal necrosis secondary to varicella zoster virus in acquired immune deficiency syndrome. *Retina* 15:14-20, 1995.

Barber BA, Pegram PS, High KP. Clindamycin/primaquine as prophylaxis for *Pneumocystis carinii* pneumonia. *Clin Infect Dis* 23:718-722, 1996.

Wise R, Acar JF, Aldridge KE, Barry AL, Dunn DL, Iravani A, Meyers BR, Paladino JA, Pegram PS, Peterson LR, Weinstein RA. Panel discussion III. The apocalyptic bacterium is approaching fast: What can we do? *Infectious Diseases in Clinical Practice* 7:S184-S187, 1998.

Freedman BI, Soucie JM, Stone SM, Pegram S. Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy. *Am. J. Kidney Dis.* 34:254-258, 1999.

Williamson JC, Pegram PS. Respiratory distress associated with zanamivir. *New Engl. J Med* 342:661-662, 2000.

Girard P-M, Pegram PS, Diquet B, Anderson R, Raffi F, Tubiana R, Sereni D, Boerner D. Phase II placebo-controlled trial of fozivudine tidoxil for HIV infection: Pharmacokinetics, tolerability, and efficacy. *J Acquir Immune Defici Syndr* 23:227-235, 2000.

Williamson JC, Pegram PS. Neuraminidase inhibitors in patients with underlying airways disease. *Am J Respir Med* 1:85-90, 2002.

ABSTRACTS:

Pegram PS Jr., Muss HB, McCall CE, Cooper MR, White DR, Richards FII, Jackson DV Jr., Stuart JJ, Spurr CL. A comparative study of moxalactam (M) vs. ticarcillin and tobramycin (TT) in febrile, neutropenic cancer patients. *Proc ASCO* 1:66, 1982.

Pegram PS Jr., Muss H, McCall C, Cooper R, White D, Richards F, Jackson D, Stuart J, Spurr C, Hopkins J, Capizzi R. A comparative study of moxalactam (M) and tobramycin/ticarcillin (TT) in febrile neutropenic patients. *Proc ASCO* 3:100, 1984.

Phair J, Pegram S, Murphy R, Savateer S, Washton H, Cohen M. A collaborative trial of cefoperazone plus tobramycin versus cefoperazone plus tobramycin with tobramycin discontinued after 4 days versus mezlocillin plus tobramycin as empiric treatment in febrile neutropenic patients. In: *International Congress of Chemotherapy (14th: 1985: Kyoto, Japan)*. Abstracts: Japan Convention Services 139, 1985.

Bernstein J, Gorse G, Linzmeyer I, Pegram S, Leirn R. Randomized comparison of netilmicin and piperacillin with tobramycin and piperacillin in the empiric therapy of infections in compromised hosts. In: *International Congress of Chemotherapy (14th: 1985: Kyoto, Japan)*. Abstracts: Japan Convention Services 183, 1985.

Pegram S, Muss H, Phair J, Cohen M. A comparative study of cefoperazone and tobramycin (including discontinuation limb) vs. mezlocillin and tobramycin in febrile granulocytopenic (F⁺G⁺) patients. *Proc ASCO* 5:258, 1986.

Pegram S, Phair J, Cohen M, Washton H. Aminoglycoside discontinuation following initial empiric combination therapy of febrile (F⁺) granulocytopenic (G⁺) patients. In: *Abstracts of the IXth International Congress of Infectious and Parasitic Diseases, Munich, July 20-26, 1986*. München: Futuramed Verlag, Abstr no.771, 1986.

Pegram S, Peacock J, Cruz J, Powell B, Capizzi R. A comparative study of vancomycin/ceftazidime vs. cefoperazone/ampicillin/sulbactam in febrile granulocytopenic patients. In: *Proc ASCO* 7:295, 1988.

Christensen JG, Harrison LH, Pegram S. Urological manifestations of HIV infection. *J Urol* 139:166A, 1988.

Pegram PS. A comparative trial of cefoperazone plus ampicillin/sulbactam versus ceftazidime plus vancomycin in febrile, granulocytopenic patients. Abstracts: *Major developments in the management of bacterial infections, Vancouver*, p.81, 1989.

Goldberg LH, Kaufman R, Batenhorst R, The Acyclovir Study Group. Safety and efficacy of long-term suppressive oral acyclovir (ACV) for the treatment of frequently recurring genital herpes: 4th year results. In: *Program and Abstracts 29th Intersci Conf Antimicrob Agents Chemother, Houston, 17-20 September 1989 (Amer Soc Microbial)*, p.110, Abstr no. 54, 1989.

Stein A, Luskin-Hawk R, Pegram SP, et al. Efficacy of efavirenz in combination with stavudine and didanosine in antiretroviral naïve HIV-infected patients. *ICAAC*. Sept. 26-29, 1999.

POSTERS:

Thomason JL, Gelbart SM, Scaglione NJ, James JA, Leong F, Brackhuizen FF, Pegram PS. Does cefmetazole compare to cefoxitin or penicillin for treatment of gonorrhea? Results of the multicenter study. 31st Inter science Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. 1991.

Horn CA, Washburn RG, Peacock JE, Pegram PS. Azole-resistant progressive oropharyngeal and esophageal candidiasis in patients with AIDS: a re-emerging indication for amphotericin B. Abstract 1221. 34th ICAAC. 1994.

Mildvan D, Creagh T, Leitz G, Anemia Prevalence Study Group [P. Samuel Pegram, participating investigator]. Greater prevalence of anemia in women and African Americans with HIV/AIDS in the HAART era: A study of ~10,000 patients. As presented at the 40th Annual Meeting of the Infectious Diseases Society of America, Chicago, IL, October 24-27, 2002.

Pimpawan Boapimp, Charles A. de Comarmond, Jason Kettler, Samuel Pegram, Aimee Wilkin. Predictors of Neurosyphilis in HIV-infected Patients with Positive Rapid Plasma Reagin Test. Abstracts from 43rd Annual Meeting of IDSA September 2005;

SLIDES:

Pegram PS Jr., Camp MG, McCall CE. Microorganism resistance to antibiotics. Chapel Hill, NC, Health Science Consortium, 9 slides, Col, B and W, 2 x 2 in, and study guide, 1977.

MISCELLANEOUS:

Pegram PS (reviewer). Imaging of infectious and inflammations of the central nervous system: computed tomography, ultrasound, and nuclear magnetic resonance. Surg Neurol 24:233-234, 1985. (Book Review)

Pegram PS, Washburn RG. Correcting a spelling error. Am Soc Microbial News 60:169, 1994.

Pegram PS. Treating HIV infection: a question of ethics. NC Med J 55:512, 1994.

COMMUNITY SERVICE:

Physician volunteer Community Clinic of High Point

PERSONAL INTEREST:

Cooking, travel, photography